Effects of AS2819899, a novel selective PI3Kδ inhibitor, in a NZB/W F1 mouse lupus-like nephritis model
Yoko Kaneko(Keio University), Tatsuaki Morokata(Astellas Pharma (Japan)), Takanori Marui(Astellas Pharma (Japan)), Koji Kato(AbbVie (United States)), Kaoru Yamagami(Astellas Pharma (Japan)), Misato Ito(Fukushima Medical University), Tomoko Kawashima(Astellas Pharma (Japan)), Masahiko Akamatsu(Astellas Pharma (Japan)), Fumie Takahashi(Astellas Pharma (Japan)), Hidehiko Fukahori(Astellas Pharma (Japan))
Cited by 4
Related Papers
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
NAK is an IκB kinase-activating kinase
|Nature|2000|374
STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells
|Oncogene|2004|306
Growth arrest‐specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway
|Molecular Carcinogenesis|2006|108